Circulating microRNAs in Small Testicular Masses and Retroperitoneal Post-chemotherapy Residual Masses.

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Sep 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of certain tiny molecules called microRNAs found in the blood to help detect testicular cancer in patients. The focus is on men who have either a small testicular mass (less than 2 cm) or residual masses in the lymph nodes after chemotherapy. The goal is to see if these microRNAs can provide useful information to guide doctors in deciding whether surgery can be performed to remove the affected tissue while preserving healthy parts of the testis or lymph nodes.

To participate in the trial, men aged 18 and older may be eligible if they have a single testicular lesion that’s small or if they have post-chemotherapy lymph node lesions of a certain size. Importantly, participants must have negative blood tests for tumor markers, which means there are no signs of active cancer in the bloodstream. If you join the study, you'll receive regular monitoring and tests to evaluate the microRNAs in your blood, which could help improve the way your doctors diagnose and treat testicular cancer in the future.

Gender

MALE

Eligibility criteria

• COHORT A:
• Inclusion Criteria:
• • Age \>= 18 years
• • Single testicular lesion, with \< 2 cm diameter and \< 30 % testicular volume involvement;
• • Negative Serum Tumour Markers;
• • Suitable for testis sparing surgery;
• • Informed consent.
• Exclusion Criteria:
• • None
• COHORT B:
• Inclusion Criteria:
• • Age \>= 18 years
• • Single/multiple post-chemotherapy retroperitoneal lymph node lesion, with \> 1 cm (non seminomatous) / \> 3 cm (seminomatous) diameter in patients with previous testicular germ cell primary tumour;
• • Negative Serum Tumour Markers;
• • Suitable for retroperitoneal lymph node dissection;
• • Informed consent.
• Exclusion Criteria:
• • None